OpZira

Executive Summary

OpZira is a US-based diagnostics company founded in 2020 and headquartered in San Francisco, focusing on early detection and comprehensive monitoring of ocular diseases. Its mission is to preserve vision and improve patient quality of life by equipping clinicians with advanced diagnostic tools. The company operates in the underserved ophthalmic diagnostics space, where early intervention can significantly alter disease progression and patient outcomes. Despite being in an early stage with limited public information—no disclosed funding, valuation, or specific product pipeline—OpZira's niche focus and alignment with the growing demand for non-invasive, accessible eye care diagnostics present a compelling opportunity. The company's private status and lack of disclosed milestones introduce uncertainty, but its potential to address a critical gap in ophthalmology makes it a candidate for future growth, contingent on successful product development and market adoption.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round60% success
• Q4 2026First FDA Clearance for Diagnostic Device40% success
• TBDStrategic Partnership with Major Ophthalmology Provider50% success